Fig. 6.
SEM of T. spiralis ML collected from infected non-treated (Group III) and therapeutically-treated mice (Group V): (A–B) ML retrieved from infected non-treated mice (Group III); (A) Normal ML showing idiosyncratic coiling of anteriorly tapered body and evident hypodermal gland openings (x500); (B) mid body showing shallow longitudinal groove perpendicular to the annulated cuticle (x4000). (C–E) ML collected from CWP-treated mice (Subgroup Va); (C) uncoiled ML with widened hypodermal gland openings (x400); (D) extensive furrowing of the longitudinal grooves (x4000); (E) cuticular blebs and protrusion (x4000). (F–H) ML retrieved from TWH-treated mice (Subgroup Vb); (F) Loosely coiled ML showing noticeable surface erosions and cauliflower mass (x500); (G) ulcerating cauliflower mass along with widened hypodermal gland openings (x4000); (H) bursting body extravasating the underlying ML content (x4000). (I–K) ML collected from ALB-treated mice (Subgroup Vc); (I) Loosely coiled ML lost its annulations with deepening of longitudinal grooves (x500); (J) multiple surface blebs on smooth cuticles (x4000); (K) Multiple longitudinal cuticular gaps (x4000)
